Elicio Therapeutics ELTX
NASDAQ ELTX
$1.63 +0.02 (+1.24%)
At close: Nov 11, 2026 · 4:00 PM EST

Elicio Therapeutics (ELTX) Preferred Stock Liabilities (2021 - 2023)

Updated

Elicio Therapeutics (ELTX) posted Preferred Stock Liabilities of $111.06 million for Q1 2023, up 57.7% from $70.44 million a year earlier and unchanged from the prior quarter.

Analysis

Elicio Therapeutics (ELTX) Preferred Stock Liabilities (2021 - 2023) Analysis & Trends

Since Q4 2021, Elicio Therapeutics has reported Preferred Stock Liabilities for 6 quarters.

  • In prior years, Elicio Therapeutics' Preferred Stock Liabilities was $70.44 million in FY2021.
  • According to Business Quant data, Preferred Stock Liabilities for the three prior quarters was $111.06 million (Q4 2022), $80.45 million (Q3 2022) and $71.61 million (Q2 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Elicio Therapeutics 45.57 Mn -42.34 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 111.06 Mn
Dec 31, 2022 111.06 Mn
Sep 30, 2022 80.45 Mn
Jun 30, 2022 71.61 Mn
Mar 31, 2022 70.44 Mn
Dec 31, 2021 70.44 Mn
API Access

Elicio Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ELTX&period=max&api_key=YOUR_API_KEY